Notably, Gal-9 exists in multiple isoforms with distinct binding affinities for TIM-3, and its extracellular release can create localized immunosuppressive niches that extend beyond direct cell–cell interactions, potentially affecting distant immune effector cells within the tumour microenvironment [53,54,55,56]. Here, LGALS9 is linked to neoplasm.